Sio Gene Therapies Inc. (SIOX)


-0.01 (-4.89%)
Symbol SIOX
Price $0.2901
Beta 1.560
Volume Avg. 0.23M
Market Cap 21.460M
Shares () -
52 Week Range 0.23-2.655
1y Target Est -
DCF Unlevered SIOX DCF ->
DCF Levered SIOX LDCF ->
ROE -59.73% Strong Sell
ROA -68.77% Strong Sell
Operating Margin -
Debt / Equity 20.67% Neutral
P/E -
P/B 0.41 Neutral


Consensus EPS

Upgrades & Downgrades

Latest SIOX news

NASDAQ Global Select

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.